Titan Pharmaceuticals, Inc. common stock (TTNP) Stock: Do Analysts Think You Should Buy?

Tuesday, December 21, 2021 09:55 AM | InvestorsObserver Analysts

Mentioned in this article

Analysts who follow Titan Pharmaceuticals, Inc. common stock (TTNP) on average expect it to add 400.00% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 74, which means it ranks higher than 74 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating TTNP a Strong Buy today. Find out what this means to you and get the rest of the rankings on TTNP!
See Full TTNP Report

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Titan Pharmaceuticals, Inc. common stock Stock Today?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is trading at $1.40 as of 9:55 AM on Tuesday, Dec 21, an increase of $0.33, or 30.84% from the previous closing price of $1.07. The stock has traded between $1.12 and $1.44 so far today. Volume today is elevated. So far 483,377 shares have traded compared to average volume of 99,118 shares. Click Here to get the full Stock Report for Titan Pharmaceuticals, Inc. common stock stock.

Share this article:

Related Articles